{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:12:39Z","timestamp":1788772359414,"version":"build-2803163510"},"reference-count":131,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Obesity is a long-term, complex disorder characterised by excessive adiposity that increases the risk of metabolic and cardiovascular diseases. Obesity is a significant health problem, with its prevalence increasing steadily over the last several decades. This rising trend has contributed substantially to the burden of metabolic, cardiovascular and other chronic diseases. Lifestyle modification remains the primary approach to obesity treatment; long-term weight reduction is difficult to achieve and sustain due to complex neurohormonal mechanisms that regulate appetite and energy homeostasis. Consequently, pharmacotherapy has become an essential component of comprehensive obesity management in appropriately selected patients. Recent advances in obesity pharmacology have revolutionised treatment strategies, particularly with the introduction of incretin-based therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic polypeptide (GIP)\/GLP-1 receptor agonists, which have demonstrated unprecedented efficacy in achieving clinically meaningful and sustained weight loss. Furthermore, several novel agents, including triple agonists, oral peptide formulations, and combination therapies, are currently undergoing clinical evaluation and are expected to further transform obesity treatment. This review provides the current understanding of obesity pharmacotherapy, discusses approved anti-obesity medications, highlights emerging therapeutic agents and drugs under clinical development, and explores future perspectives in obesity management. Additionally, the review addresses current challenges, safety concerns, and public health strategies required to combat the growing obesity epidemic.<\/jats:p>","DOI":"10.3389\/fendo.2026.1933913","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:03:50Z","timestamp":1788771830000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in the management of obesity: non-pharmacological strategies, herbal formulations, current pharmacotherapy, emerging drugs, and future perspectives"],"prefix":"10.3389","volume":"17","author":[{"given":"Kaushal Navanath","family":"Mehetre","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Bharati Vidyapeeth (Deemed to be University) Medical College","place":["Pune, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayshree Shriram","family":"Dawane","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Bharati Vidyapeeth (Deemed to be University) Medical College","place":["Pune, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/obr.70163","article-title":"National and international clinical guidelines for the management of obesity in adults: A systematic review","author":"Doody","year":"2026","journal-title":"Obes Rev"},{"key":"B2","volume-title":"World Obesity Atlas 2025","year":"2025"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.24288","article-title":"World Health Organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults","volume":"335","author":"Celletti","year":"2026","journal-title":"JAMA"},{"key":"B4","volume-title":"The WHO Acceleration Plan to Stop Obesity: A Joint Who\/Unicef Operational Model for Designing and Implementing the Response","year":"2026"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02750-2","article-title":"Worldwide trends in body-mass index from 1990 to 2022: A pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1514009","article-title":"Mechanisms, pathophysiology, and management of obesity","volume":"376","author":"Heymsfield","year":"2017","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229438","article-title":"Forecasting the prevalence of overweight and obesity in India to 2040","volume":"15","author":"Luhar","year":"2020","journal-title":"PloS One"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00337-8","article-title":"Anti-obesity drug discovery: Advances and therapeutic opportunities","volume":"21","author":"M\u00fcller","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12264-024-01335-7","article-title":"Neuronal regulation of feeding and energy metabolism: A focus on the hypothalamus and brainstem","volume":"41","author":"Chen","year":"2025","journal-title":"Neurosci Bull"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-00912-3","article-title":"Emerging therapeutic targets for obesity: FGF21, GDF15, brown adipose tissue activation, and gut microbiota modulation","volume":"23","author":"M\u00fcller","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.16263","article-title":"An overview of obesity-related complications: The epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes","author":"Bl\u00fcher","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30175-1","article-title":"Body-mass index and all-cause mortality: Individual-participant-data meta-analysis of 239 prospective studies in four continents","volume":"388","author":"Di Angelantonio","year":"2016","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.001","article-title":"American Association of Clinical Endocrinology clinical practice guideline for obesity","volume":"28","author":"Garvey","year":"2022","journal-title":"Endocr Pract"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-023-00887-4","article-title":"Obesity-induced and weight-loss-induced physiological factors affecting weight regain","volume":"19","author":"Van Baak","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.250502","article-title":"Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update","volume":"197","author":"Pedersen","year":"2025","journal-title":"CMAJ"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03978-z","article-title":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","volume":"31","author":"McGowan","year":"2025","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone receptor agonist retatrutide for obesity \u2014 a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0803-x","article-title":"Joint international consensus statement for ending stigma of obesity","volume":"26","author":"Rubino","year":"2020","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00002.2024","article-title":"The (dys)regulation of energy storage in obesity","volume":"105","author":"Levin","year":"2025","journal-title":"Physiol Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1172060","article-title":"Recent progress on action and regulation of anorexigenic adipokine leptin","volume":"14","author":"Nakagawa","year":"2023","journal-title":"Front Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1186\/s12967-025-06656-3","article-title":"The central signaling pathways related to metabolism-regulating hormones of the gut-brain axis: A review","volume":"23","author":"Liu","year":"2025","journal-title":"J Transl Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-nutr-062122-031443","article-title":"Energy expenditure in humans: Principles, methods, and changes throughout the life course","volume":"44","author":"Fern\u00e1ndez-Verdejo","year":"2024","journal-title":"Annu Rev Nutr"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22189","article-title":"Metabolic adaptations to weight loss","volume":"26","author":"Hall","year":"2018","journal-title":"Obes (Silver Spring)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00421-017-3641-x","article-title":"Doubly labelled water assessment of energy expenditure: Principle, practice, and promise","volume":"117","author":"Westerterp","year":"2017","journal-title":"Eur J Appl Physiol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/bjsports-2018-099643","article-title":"How well do activity monitors estimate energy expenditure? A systematic review and meta-analysis of the validity of current technologies","volume":"54","author":"O'Driscoll","year":"2020","journal-title":"Br J Sports Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156053","article-title":"Evidence from clinical studies of leptin: Current and future clinical applications in humans","volume":"161","author":"Perakakis","year":"2024","journal-title":"Metabolism"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00250.2023","article-title":"Brain access of incretins and incretin receptor agonists to their central targets relevant for appetite suppression and weight loss","volume":"326","author":"Buller","year":"2024","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-023-00927-z","article-title":"The intersection between ghrelin, metabolism and circadian rhythms","volume":"20","author":"Kulkarni","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2024.105907","article-title":"Central effects of acute intranasal insulin on neuroimaging, cognitive, and behavioural outcomes: A systematic review","volume":"167","author":"Tabassum","year":"2024","journal-title":"Neurosci Biobehav Rev"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108699","article-title":"Tissue-specific activation of insulin signaling as a potential target for obesity-related metabolic disorders","volume":"262","author":"Okuma","year":"2024","journal-title":"Pharmacol Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-024-01113-9","article-title":"GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management","volume":"6","author":"Holst","year":"2024","journal-title":"Nat Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000859","article-title":"Gut hormones and appetite regulation","volume":"31","author":"Hong","year":"2024","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.diff.2024.100832","article-title":"Deciphering endocrine function of adipose tissue and its significant influences in obesity-related diseases caused by its dysfunction","volume":"141","author":"Duan","year":"2025","journal-title":"Differentiation"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.7570\/jomes24013","article-title":"Understanding adipose tissue dysfunction","volume":"33","author":"Bl\u00fcher","year":"2024","journal-title":"J Obes Metab Syndr"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13724","article-title":"Inflammation-mediated metabolic regulation in adipose tissue","volume":"25","author":"Xu","year":"2024","journal-title":"Obes Rev"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13956","article-title":"Is adipose tissue inflammation the culprit of obesity-associated comorbidities","volume":"26","author":"Turner","year":"2025","journal-title":"Obes Rev"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1128\/jb.00479-24","article-title":"Unraveling the gut microbiota\u2019s role in obesity: Key metabolites, microbial species, and therapeutic insights","volume":"207","author":"Iqbal","year":"2025","journal-title":"J Bacteriol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00045-23","article-title":"Role of the intestinal microbiota in contributing to weight disorders and associated comorbidities","volume":"37","author":"Van Hul","year":"2024","journal-title":"Clin Microbiol Rev"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqae167","article-title":"GLP-1 and the neurobiology of eating control","volume":"166","author":"Jones","year":"2025","journal-title":"Endocrinology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s13668-026-00732-w","article-title":"The gut-brain axis in obesity: Mechanisms, development, and therapeutic perspectives","volume":"15","author":"Arellano-Garc\u00eda","year":"2026","journal-title":"Curr Nutr Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2024.2365785","article-title":"The complex web of obesity: From genetics to precision medicine","volume":"19","author":"Nair","year":"2024","journal-title":"Expert Rev Endocrinol Metab"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/abp.2026.15484","article-title":"Genetic architecture of obesity and advances in precision pharmacotherapy: A comprehensive review","volume":"73","author":"Kavaja","year":"2026","journal-title":"Acta Biochim Pol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1171","article-title":"Epigenetics in obesity: Mechanisms and advances in therapies based on natural products","volume":"12","author":"Chen","year":"2024","journal-title":"Pharmacol Res Perspect"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2024.109832","article-title":"Thermogenic adipose tissues: Promising therapeutic targets for metabolic diseases","volume":"137","author":"Pahlavani","year":"2025","journal-title":"J Nutr Biochem"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252413295","article-title":"Brown and beige adipose tissue: One or different targets for treatment of obesity and obesity-related metabolic disorders","volume":"25","author":"Kononova","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2025.103208","article-title":"Efficacy of microbiome-targeted interventions in obesity management- A comprehensive systematic review","volume":"19","author":"Dhanasekaran","year":"2025","journal-title":"Diabetes Metab Syndr"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2026.03.056","article-title":"2026 AHA\/ACC\/ADA\/ASN guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Ndumele","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/27697061.2024.2440051","article-title":"Effect of Mediterranean diets on cardiovascular risk factors and disease in overweight and obese adults: A systematic review and meta-analysis of randomized controlled trials","volume":"44","author":"Hernandez","year":"2025","journal-title":"J Am Nutr Assoc"},{"key":"B51","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.clnesp.2024.08.023","article-title":"Comparison of weight loss effects among overweight\/obese adults: A network meta-analysis of Mediterranean, low carbohydrate, and low-fat diets","volume":"64","author":"Akbari","year":"2024","journal-title":"Clin Nutr ESPEN"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/obr.70037","article-title":"Impacts of lifestyle and microbiota-targeted interventions for overweight and obesity on the human gut microbiome: A systematic review","volume":"27","author":"Lee","year":"2026","journal-title":"Obes Rev"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.8490","article-title":"Plant-derived natural products for dietary intervention in overweight and obese individuals: a systematic review and network meta-analysis","volume":"39","author":"Wiyarta","year":"2025","journal-title":"Phytother Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/nu17162683","article-title":"Comparison with dietary groups of various macronutrient ratios on body weight and cardiovascular risk factors in adults: A systematic review and network meta-analysis","volume":"17","author":"Lou","year":"2025","journal-title":"Nutrients"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-024-01664-7","article-title":"Assessing the evidence for health benefits of low-level weight loss: A systematic review","volume":"49","author":"Dhar","year":"2025","journal-title":"Int J Obes (Lond)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s00421-023-05370-6","article-title":"Obesity blunts insulin sensitivity improvements and attenuates strength gains following resistance training in nondiabetic men","volume":"124","author":"Al-Horani","year":"2024","journal-title":"Eur J Appl Physiol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13102-024-00894-6","article-title":"The effects of kettlebell training versus resistance training using the own body mass on physical fitness and physiological adaptations in obese adults: A randomized controlled trial","volume":"16","author":"Govindasamy","year":"2024","journal-title":"BMC Sports Sci Med Rehabil"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13798","article-title":"Which components of behavioral weight management programs are essential for weight loss in people living with obesity? A rapid review of systematic reviews","volume":"25","author":"Hawkins","year":"2024","journal-title":"Obes Rev"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13871","article-title":"The impact of behavioral weight management interventions on eating behavior traits in adults with overweight or obesity: A systematic review and meta-analysis","volume":"26","author":"Kudlek","year":"2025","journal-title":"Obes Rev"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1177\/1357633X241273991","article-title":"Effect of telemedicine interventions on weight loss: A systematic review and meta-analysis","volume":"31","author":"Moulaei","year":"2025","journal-title":"J Telemed Telecare"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2196\/67601","article-title":"The role of mobile apps in obesity management: Systematic review and meta-analysis","volume":"27","author":"Pujia","year":"2025","journal-title":"J Med Internet Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.772","article-title":"Short sleep duration is associated with higher risk of central obesity in adults: A systematic review and meta-analysis of prospective cohort studies","volume":"10","author":"Kohanmoo","year":"2024","journal-title":"Obes Sci Pract"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12634","article-title":"The relationship between sleep quantity, sleep quality and weight loss in adults: A scoping review","volume":"14","author":"Knowlden","year":"2024","journal-title":"Clin Obes"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2022.08.013","article-title":"2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for metabolic and bariatric surgery","volume":"18","author":"Eisenberg","year":"2022","journal-title":"Surg Obes Relat Dis"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znae283","article-title":"International consensus position statement on the role of obesity management medications in the context of metabolic bariatric surgery: Expert guideline by the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)","volume":"111","author":"Cohen","year":"2024","journal-title":"Br J Surg"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.3073","article-title":"A systematic review of herbal medicines for obesity and their active ingredients","volume":"15","author":"Hasani-Ranjbar","year":"2009","journal-title":"World J Gastroenterol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052671","article-title":"Clinically effective molecules of natural origin for obesity prevention or treatment","volume":"25","author":"Hidalgo-Lozada","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3945\/an.112.003517","article-title":"Health-promoting components of fruits and vegetables in the diet","volume":"4","author":"Liu","year":"2013","journal-title":"Adv Nutr"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s44187-025-00628-8","article-title":"Green tea supplementation in adults with obesity: A systematic review of clinical studies","volume":"5","author":"Au-Doung","year":"2025","journal-title":"Discover Food"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/509038","article-title":"The use of Garcinia extract (Hydroxycitric Acid) as a weight loss supplement: A systematic review and meta-analysis of randomised clinical trials","volume":"2011","author":"Onakpoya","year":"2011","journal-title":"J Obes"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2014.09.004","article-title":"The effect of glucomannan on body weight in overweight or obese children and adults: A systematic review of randomized controlled trials","volume":"31","author":"Zalewski","year":"2015","journal-title":"Nutrition"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.7512","article-title":"Botanical and herbal dietary supplements for weight loss: A comprehensive review","volume":"36","author":"Yang","year":"2022","journal-title":"Phytother Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1080\/10408398.2018.1427044","article-title":"The effects of ginger intake on weight loss and metabolic profiles among overweight and obese subjects: A systematic review and meta-analysis of randomized controlled trials","volume":"59","author":"Maharlouei","year":"2019","journal-title":"Crit Rev Food Sci Nutr"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.154680","article-title":"Effects of Trigonella foenum-graecum (Fenugreek) on metabolic parameters and weight management: A systematic review","volume":"112","author":"Fulla","year":"2023","journal-title":"Phytomedicine"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2022.115820","article-title":"Gymnema sylvestre for the management of obesity and diabetes: Mechanisms of action and clinical evidence","volume":"301","author":"Devangan","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00649","article-title":"The effects of curcumin on weight loss among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Akbari","year":"2019","journal-title":"Front Pharmacol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40608-018-0197-1","article-title":"Capsaicinoids supplementation decreases body fat and fat mass in healthy humans","volume":"5","author":"Rogers","year":"2018","journal-title":"BMC Obes"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-025-02738-6","article-title":"Berberine as a multi-target therapeutic agent for obesity: From pharmacological mechanisms to clinical evidence","volume":"121","author":"Zhang","year":"2025","journal-title":"Phytomedicine"},{"key":"B79","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/2156587216641830","article-title":"Body weight management in adults under chronic stress through treatment with ashwagandha root extract: A double-blind, randomized, placebo-controlled trial","volume":"22","author":"Choudhary","year":"2017","journal-title":"J Evid Based Complementary Altern Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1080\/19390211.2021.1887423","article-title":"Anti-obesity potential of Triphala and its constituent botanical components: A systematic review of preclinical and clinical data","volume":"19","author":"Darvesh","year":"2022","journal-title":"J Diet Suppl"},{"key":"B81","doi-asserted-by":"publisher","first-page":"100002","DOI":"10.1124\/pharmrev.123.001045","article-title":"Emerging pharmacotherapies for obesity: A systematic review","volume":"77","author":"Kokkorakis","year":"2025","journal-title":"Pharmacol Rev"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2026-372161","article-title":"Comparative effects of drugs for adults with overweight or obesity: Systematic review and network meta-analysis","volume":"394","author":"Nong","year":"2026","journal-title":"BMJ"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.5414\/CP204585","article-title":"Rational use of short-term anorectic drugs for one-year effective treatment of obesity: An analysis of four studies","volume":"62","author":"Galicia-Quintanar","year":"2024","journal-title":"Int J Clin Pharmacol Ther"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: A randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2012","journal-title":"Obes (Silver Spring)"},{"key":"B86","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2200014","article-title":"Phentermine\/Topiramate for the treatment of adolescent obesity","volume":"1","author":"Kelly","year":"2022","journal-title":"NEJM Evid"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.13143","article-title":"Effectiveness and predictors of weight loss response to phentermine plus lifestyle modifications among youth in a paediatric weight management clinical setting","volume":"19","author":"Bomberg","year":"2024","journal-title":"Pediatr Obes"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-025-06873-0","article-title":"The weight reducing effects of naltrexone-bupropion among obese psychiatric and non-psychiatric patients: A systematic review","volume":"242","author":"Alim Ur Rahman","year":"2025","journal-title":"Psychopharmacol (Berl)"},{"key":"B90","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13098-024-01319-7","article-title":"The effects of bupropion alone and combined with naltrexone on weight loss: A systematic review and meta-regression analysis of randomized controlled trials","volume":"16","author":"Liu","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15113","article-title":"Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes","volume":"25","author":"Silver","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.39848","article-title":"Liraglutide and weight loss among suboptimal responders to metabolic bariatric surgery: A randomized clinical trial","volume":"8","author":"Brown","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23512","article-title":"Gastrointestinal tolerability and weight loss with semaglutide 2.4 mg in STEP 1-5 trials","volume":"30","author":"Wharton","year":"2022","journal-title":"Obes (Silver Spring)"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2500969","article-title":"Once-daily oral semaglutide 25 mg in adults with overweight or obesity (OASIS 4): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"405","author":"Wharton","year":"2025","journal-title":"Lancet"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2024.11.008","article-title":"Treatment persistence and real-world outcomes with incretin-based therapies for obesity","volume":"31","author":"Weiss","year":"2025","journal-title":"Endocr Pract"},{"key":"B97","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-026-01427-1","article-title":"The evolving landscape of obesity pharmacotherapy","volume":"25","author":"Petersen","year":"2026","journal-title":"Nat Rev Drug Discov"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist, enhances energy expenditure and weight loss in rodents","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metab"},{"key":"B101","article-title":"The first phase 3 obesity study of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with obesity (TRIUMPH-1)","author":"Jastreboff","year":""},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a triple GIP\/GLP-1\/glucagon receptor agonist, in adults with type 2 diabetes: A phase 2, randomized, double-blind, placebo- and dulaglutide-controlled trial","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304878","article-title":"Orforglipron, a nonpeptide GLP-1 receptor agonist, in adults with obesity or overweight","volume":"389","author":"Pratt","year":"2023","journal-title":"N Engl J Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01302-8","article-title":"Orforglipron versus dulaglutide or placebo in type 2 diabetes: A phase 2 randomized trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"N Engl J Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight or obesity: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"key":"B107","volume-title":"Cagrisema Demonstrated 23% Weight Loss in an Open-Label Head-to-Head REDEFINE 4 Trial in People With Obesity; the Primary Endpoint was Not Achieved","year":"2026"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01185-7","article-title":"Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: Results from a phase 1b\/2a randomised controlled study","volume":"406","author":"Dahl","year":"2025","journal-title":"Lancet"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2504214","article-title":"Once-monthly maridebart cafraglutide for the treatment of obesity\u2014a phase 2 trial","volume":"393","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1002\/oby.70106","article-title":"Weekly subcutaneous VK2735, a GIP\/GLP-1 receptor dual agonist, for weight management: Phase 2, randomized, 13-week VENTURE study","volume":"34","author":"Bays","year":"2026","journal-title":"Obes (Silver Spring)"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2600751","article-title":"Survodutide once weekly for the treatment of adults with obesity","volume":"395","author":"le Roux","year":"2026","journal-title":"N Engl J Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2600751","article-title":"Survodutide once weekly for the treatment of adults with obesity without diabetes","volume":"395","author":"le Roux","year":"2026","journal-title":"N Engl J Med"},{"key":"B113","doi-asserted-by":"publisher","first-page":"7854","DOI":"10.1038\/s41467-023-44067-4","article-title":"Mazdutide (IBI362), a dual GLP-1 and glucagon receptor agonist, in Chinese adults with overweight or obesity: A phase 2 randomized controlled trial","volume":"14","author":"Ji","year":"2023","journal-title":"Nat Commun"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16047","article-title":"Non-clinical and first-in-human characterization of ECC5004\/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist","volume":"27","author":"Haggag","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2025.102291","article-title":"Phase 1b trial results for CT-388, a once-weekly dual GLP-1\/GIP receptor agonist in adults with obesity","volume":"404","year":"2024","journal-title":"Lancet"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.31525\/ct1-nct03917628","article-title":"ECC5004, a novel oral small-molecule GLP-1 receptor agonist: Phase 1 safety, tolerability, and pharmacokinetics in healthy volunteers and adults with type 2 diabetes","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.7602","article-title":"Association of pharmacological treatments for obesity with weight loss and adverse events: A systematic review and meta-analysis","volume":"315","author":"Khera","year":"2016","journal-title":"JAMA"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01640-8","article-title":"Pharmacotherapy for adults with overweight and obesity: A systematic review and network meta-analysis of randomised controlled trials","volume":"399","author":"Shi","year":"2022","journal-title":"Lancet"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2500969","article-title":"Oral semaglutide at a dose of 25 mg in adults with overweight or obesity","volume":"393","author":"Wharton","year":"2025","journal-title":"N Engl J Med"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.08.045","article-title":"AGA clinical practice guideline on pharmacological interventions for adults with obesity","volume":"163","author":"Grunvald","year":"2022","journal-title":"Gastroenterology"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-03764","article-title":"Benefits and harms of pharmacologic treatments in adults with overweight or obesity: A living systematic review and network meta-analysis for the American College of Physicians","volume":"179","author":"Damen","year":"2026","journal-title":"Ann Intern Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511774","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment","volume":"393","author":"Wharton","year":"2025","journal-title":"N Engl J Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-025-02700-7","article-title":"Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan","volume":"48","author":"Tuccinardi","year":"2025","journal-title":"J Endocrinol Invest"},{"key":"B124","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/oby.70095","article-title":"Artificial intelligence across the obesity continuum: From mechanistic insights to global precision prevention and therapy","volume":"34","author":"Wang","year":"2026","journal-title":"Obes (Silver Spring)"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3390\/nu17132200","article-title":"E-health and m-health in obesity management: A systematic review and meta-analysis of RCTs","volume":"17","author":"Chiavarini","year":"2025","journal-title":"Nutrients"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13944","article-title":"Associations between the built environment and adult obesity and the mediating role of physical activity: A systematic review","volume":"26","author":"Shrestha","year":"2025","journal-title":"Obes Rev"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1159\/000546415","article-title":"Prevention of obesity among adults: Evidence- and consensus-based guideline","volume":"18","author":"von Philipsborn","year":"2025","journal-title":"Obes Facts"},{"key":"B128","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s13679-025-00639-7","article-title":"Health disparities in obesity treatment outcomes, access, and utilization","volume":"14","author":"Ross","year":"2025","journal-title":"Curr Obes Rep"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1002\/jac5.70118","article-title":"Tipping the scales: Strategies to improve anti-obesity medication access and affordability","volume":"8","author":"Kom\u00e9","year":"2025","journal-title":"J Am Coll Clin Pharm"},{"key":"B130","doi-asserted-by":"publisher","first-page":"56","DOI":"10.4103\/ijpvm.ijpvm_368_24","article-title":"Economic evaluation of medications in prevention and treatment of obesity: A systematic review","volume":"16","author":"Afshari","year":"2025","journal-title":"Int J Prev Med"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13952","article-title":"The effectiveness of partnerships with commercial actors to improve food environments: A systematic review","volume":"26","author":"Blanchard","year":"2025","journal-title":"Obes Rev"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1933913\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:03:53Z","timestamp":1788771833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1933913\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":131,"alternative-id":["10.3389\/fendo.2026.1933913"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1933913","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"1933913"}}